|
|
|
|
Besifloxacin Comparable to Moxifloxacin for Bacterial Conjunctivitis: Presented at AAO
-- Besifloxacin ophthalmic suspension 0.6% appears to be clinically equivalent to moxifloxacin ophthalmic solution 0.5% in the treatment of bacterial conjunctivitis, according to research presented here at the American Academy of...
|
|
|
Regulatory T Cells Participate in 4-1BB-Mediated Suppression of Experimental Allergic Conjunctivitis
Annals of Allergy, Asthma, and Immunology, 10/01/08 Pediatric Allergy and Immunology, 10/27/08 Regulatory T Cells Participate in 4-1BB-Mediated Suppression of Experimental Allergic Conjunctivitis.
|
|
|
Conjunctivitis treatment also improves signs, symptoms of blepharitis
Topical azithromycin is effective in conjunction with warm compresses.Stephanie Vasta A macrolide antibiotic drop approved for treating bacterial infection has also shown efficacy in treating blepharitis. Clinical trials and clinical...
|
|
|
Escherichia hermannii as the Sole Isolate from a Patient with Purulent Conjunctivitis
Poulou A et al.- Escherichia hermannii was isolated in pure culture from a patient with acute purulent conjunctivitis after a minor ocular injury. This is the first report of E. hermannii isolated as the sole pathogen from an infected...
|
|
|
Learn about the Animal Therapeutics and Diagnostics
-Reportlinker.com announces that a new market research report related to the Veterinary health industry is available in its catalogue.Animal Therapeutics and Diagnostics www.reportlinker.com/p096604/Animal-Therapeutics- and-Diagnostics...
|
|
|
Use Of An Inhibitor Of Tnfa Plus An Antihistamine To Treat Allergic Rhinitis And Allergic Conjunctivitis
ALCON RESEARCH, LTD.YANNI, John, M. GAMACHE, Daniel, A. MILLER, Steven, T. BEAUREGARD, Clay YANNI, John, M. GAMACHE, Daniel, A. MILLER, Steven, T. BEAUREGARD, ClayTitle USE OF AN INHIBITOR OF TNFA PLUS AN ANTIHISTAMINE ...
|
|
|
96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sul
PRINCETON, N.J.-(Business Wire)-October 26, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week data from the CASTLE study, in which 74 percent of the 440 patients in the REYATAZ (atazanavir sulfate)/r arm achieved an...
|
|
|
96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sul
Data continue to show differences in gastrointestinal and lipid effects among study population PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced 96-week data from the CASTLE study, in which 74...
|
|
|
96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sul
2008-10-2612:30ET - News Release Data continue to show differences in gastrointestinal and lipid effects among study population PRINCETON, N.J.-- (Business Wire) Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week data from...
|
|
|
Inspire Announces Issuance of Patent for Elestat
- (NewsRx.com) -- (NASDAQ: ISPH) announced that the U.S.Patent and Trademark Office has issued a method of treatment patent related to Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis. This patent, U.S....
|
|
|
Inspire Pharma gets US patent for Elestat
Inspire Pharmaceuticals, Inc announced that the US Patent and Trademark Office has issued a method of treatment patent related to Elestat (epinastine HCl ophthalmic solution) 0.05 per cent for allergic conjunctivitis.This patent, US...
|
|
|
Inspire Pharma Granted US Patent for Elestat 0.05% for Allergic Conjunctivitis - Quick Facts
Inspire Pharmaceuticals Inc.(ISPH: News ) said that the U.S. Patent and Trademark Office have issued a method of treatment patent related to Elestat 0.05% for allergic conjunctivitis. The company stated that the patent entitled ...
|
|
|
Inspire Announces Issuance of Patent for Elestat
- Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today that the U.S. Patent and Trademark Office has issued a method of treatment patent related to Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis...
|
|
|
Inspire Announces Issuance of Patent for Elestat(R)
Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today that the U.S. Patent and Trademark Office has issued a method of treatment patent related to Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis....
|
|
|
Leave Pink Eye off the Back-to-School List, Says AllAboutVision.com
- New teachers, new clothes and new classmates are all part of a new school year.And all too often, so is a case of pink eye. Conjunctivitis, commonly called 'pink eye,' is an inflammation of the eye's outer lining that's a common...
|
